TrademarksUSA
Akebia Therapeutics Secures Extended Patent Protection for Vafseo® Through 2043
Akebia Therapeutics has been granted a U.S. patent extending intellectual property protection for its anemia treatment Vafseo® (vadadustat) until January 18, 2043. The patent, covering methods addressing drug-drug interactions, is eligible for Orange Book listing, reinforcing Vafseo’s market exclusivity. Approved by t…
Tuesday, November 17, 2026